ACHN Achillion Pharmaceuticals Inc.

4.77
+0.05  (+1%)
Previous Close 4.72
Open 4.75
Price To Book 2.87
Market Cap 666,335,171
Shares 139,692,908
Volume 1,028,501
Short Ratio
Av. Daily Volume 1,685,597

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

End of Phase 2 meeting 4Q 2019.
ACH-4471
C3 glomerulopathy (C3G)
Janssen noted September 11, 2017 that no further development planned.
JNJ-4178
Hepatitis C (HCV)
Phase 2 full data due 4Q 2019.
Danicopan (ACH-4471)
Paroxysmal nocturnal hemoglobinuria (PNH)
Janssen noted September 11, 2017 that no further development planned.
JNJ-4178 - OMEGA-1
Hepatitis C (HCV)
End of Phase 2 meeting 4Q 2019.
ACH-4471
C3 glomerulopathy (C3G)
Phase 2 trial planned with Phase 3 trials to potentially commence in early 2020.
ACH-5228
Healthy volunteers

Latest News

  1. Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil
  2. Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update
  3. Why Achillion Pharmaceuticals Stock Flew Higher Again Today
  4. Why Achillion Pharmaceuticals Stock Is Soaring Again Today
  5. Why Luckin Coffee, Beyond Meat, and Achillion Pharmaceuticals Jumped Today
  6. Why Achillion Pharmaceuticals Stock Jumped Today
  7. Achillion’s ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers
  8. Achillion Pharmaceuticals ACHN- 2019 Top Picks' Mid-Year Update
  9. Does Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Have A High Beta?
  10. Alexion's Ultomiris Receives EU Approval for PNH in Adults
  11. Alexion Receives FDA Approval for Label Expansion of Soliris
  12. Here’s What Hedge Funds Think About Achillion Pharmaceuticals, Inc. (ACHN)
  13. Alexion's sBLA for Ultomiris Gets Priority Review From FDA
  14. Achillion to Present at the JMP Securities Life Sciences Conference
  15. Achillion Announces Upcoming Scientific Presentation at the 24th Congress of the European Hematology Association
  16. Why Is Achillion (ACHN) Down 1.4% Since Last Earnings Report?
  17. The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering
  18. Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting
  19. Achillion Granted Twentieth Patent for Factor D Portfolio
  20. Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1